About this medicine

The UK spelling Efexor differs from American Effexor. XL and XR describe prolonged-release products, but a matching alias does not prove identical instructions or licences.

Venlafaxine is regular treatment whose benefit develops over time, not an as-needed medicine for a panic attack. Follow-up considers functioning and anxiety as well as mood. Continued treatment after improvement can be appropriate to reduce recurrence.

What is this medicine used for?

The checked Efexor XL products treat adults with depression, generalised anxiety, social anxiety and panic disorder, and prevent depressive recurrence. Their anxiety indications should not automatically be assigned to immediate-release tablets.

Dexcel’s immediate-release tablets are licensed for adult major depressive episodes and prevention of recurrence. Their licence does not include the anxiety indications of the checked prolonged-release products.

Which warning signs need help?

An overdose requires immediate assessment even if the person feels well. Seek urgent help for self-harm thoughts, fever with confusion and twitching, severe restlessness, or serious palpitations. Severe allergic reactions need emergency care.

MHRA’s October 2026 communication announced the rollout of a prominent boxed warning in UK antidepressant patient leaflets about self-harm and suicidal behaviour, alongside a patient safety card. This UK patient-information measure is not the US FDA Boxed Warning designation. Read the leaflet supplied with your medicine, seek prompt professional help for new or worsening mood or behaviour changes, and do not stop treatment suddenly without advice.

How do I take it safely?

Adult XL product reference: 75 mg daily is usual initially for depression and generalised anxiety. The labelled maximum is 375 mg for depression and 225 mg for anxiety disorders. Panic treatment begins at 37.5 mg daily for seven days using a suitable product. Dose increases require clinical review. Swallow XL capsules whole; do not crush or chew.

Take the checked XL capsule with food at a consistent time; do not open, dissolve or chew it. For depression, increases are generally separated by at least two weeks, although the label allows shorter intervals in selected severe cases. That exception requires clinical evaluation, not self-escalation. Higher doses did not show added benefit for social anxiety in the cited product studies.

For the checked immediate-release tablets, the label begins at a total of 75 mg daily in two doses with food, and allows clinician-led increases up to 375 mg daily. This is separate from once-daily XL treatment. A prescriber may convert between products using the daily amount and response; do not change frequency or substitute tablets for capsules yourself.

A Genus 37.5 mg XL capsule has also been product-verified. Like the checked Efexor XL capsules, it is taken with food and swallowed whole. Its smaller strength is not permission to open a capsule or design a personal taper.

What side effects should I know about?

Nausea, dry mouth, constipation, headache, sleep disturbance, dizziness, sexual difficulties and weight changes occur. Avoid driving while dizzy or drowsy.

MHRA is adding the term post-SSRI sexual dysfunction (PSSD) to patient leaflets describing persistent sexual difficulties after stopping certain antidepressants, including this medicine. Their frequency and causes remain under study. Persistent symptoms deserve support; this does not mean everyone taking the medicine will experience them.

Who needs extra care with this medicine?

Control existing high blood pressure before treatment. Kidney or liver impairment may require lower doses. Discuss heart disease, seizures, glaucoma, bleeding and previous mania.

Low sodium can produce weakness, confusion or seizures, particularly in older or dehydrated people and those taking diuretics. Bleeding risk, a personal or family history of bipolar illness, and troublesome restlessness also need assessment. Increasing the dose can worsen akathisia rather than relieve it.

Can it affect my other medicines?

Irreversible MAO inhibitors are contraindicated. Other serotonergic medicines, St John’s wort, anticoagulants and medicines affecting heart rhythm need careful review.

The UK leaflet requires at least 14 days after an irreversible MAOI before venlafaxine and at least seven days after venlafaxine before an MAOI; the receiving medicine can require longer. Medicines for migraine, pain, infection or heart rhythm all belong in the review. The leaflet advises avoiding alcohol because it can worsen impairment and other risks.

Before a dopamine-transporter scan using ioflupane, tell the nuclear-medicine team that you take venlafaxine. MHRA has received reports of false-positive scan interpretations. Any temporary interruption must be assessed case by case; do not stop venlafaxine yourself.

What check-ups will I need?

Check blood pressure before treatment, periodically afterwards and after increases. Review mood, adverse effects and withdrawal symptoms when changing doses.

Blood pressure and pulse deserve attention during dose increases, not only before starting. New activation, sexual symptoms, bleeding or signs of low sodium also guide follow-up. Some people need additional cardiac assessment, depending on history and interacting medicines.

What about pregnancy, breastfeeding and age?

Pregnancy and breastfeeding require an individual assessment. Infants can be exposed through breast milk and may need monitoring. Efexor XL is not recommended below age 18 in the checked UK product information.

Late-pregnancy exposure may be followed by newborn breathing or feeding difficulties, and bleeding after delivery may be increased. The midwife and prescriber need to know about treatment so care can be planned. These risks are considered alongside untreated illness, not as a reason to stop abruptly.

NICE advises against using this medicine to treat depression in children and young people. Anyone already taking it should discuss an individual review and any gradual changes with the prescriber, rather than stopping suddenly.

What if I miss a dose or want to stop?

Do not stop abruptly. NICE identifies venlafaxine as particularly associated with withdrawal. Tapering may take weeks or months. Never double a missed dose.

Withdrawal may include dizziness, disturbed sleep, nausea, sweating, agitation and electric-shock-like sensations; it can be severe or prolonged. A suitable plan may need adjustment if symptoms emerge. Do not open an XL capsule or count its contents to devise a taper without product-specific professional advice.

How does it work?

Venlafaxine slows the return of serotonin and noradrenaline, two chemical messengers, into the nerve cells that released them. The body also converts it into an active substance that has similar effects. These changes are thought to contribute to improvement in mood and anxiety, although the full explanation of that benefit remains uncertain.

How Brain Cells Communicate

Nerve cells, or neurons, communicate by releasing chemical messengers called neurotransmitters into tiny gaps between cells. Serotonin and norepinephrine can then attach to receptors, proteins that detect the message and change a cell’s activity. Transporters carry some of the released messenger back into cells. This return process is called reuptake, and it helps regulate how long the messenger remains available.

What is known: Serotonin and norepinephrine are regulated partly through reuptake.

What remains uncertain: Their activity is only one part of the wider systems involved in symptoms.

Synapse with releasing vesicles, messenger in the cleft, a separate uptake transporter on the sending cell, and receiving receptors below. Sending cell: Vesicles hold chemical messengers before release. Chemical messengers: A few illustrated particles identify the messengers; their number and spacing are illustrative. Return into the sending cell: A transporter returns some messenger from the gap; it is distinct from the receiving receptor. Receiving receptor: A receptor responds to an appropriate messenger.
  1. Sending cell

    Vesicles hold chemical messengers before release.

  2. Chemical messengers

    A few illustrated particles identify the messengers; their number and spacing are illustrative.

  3. Return into the sending cell

    A transporter returns some messenger from the gap; it is distinct from the receiving receptor.

  4. Receiving receptor

    A receptor responds to an appropriate messenger.

Simplified teaching model. Protein shapes, sizes, particle counts and arrows are illustrative, not measurements or experimental structures.

Serotonin and norepinephrine are regulated partly through reuptake. Simplified illustration of the process; individual responses vary.
About this illustration

Released messengers act across a synapse; transporters return some messenger into the sending cell. Their activity is only one part of the wider systems involved in symptoms.

How the Medication Changes Signaling

Venlafaxine inhibits the reuptake of both serotonin and norepinephrine. In other words, it reduces the activity of the proteins that carry these messengers back into cells, leaving more available between cells. This action gives the medicine its class name: a serotonin and norepinephrine reuptake inhibitor, or SNRI. Changing messenger availability can alter communication, but it does not show that a person’s symptoms began with a simple shortage of either chemical.

What is known: Venlafaxine reduces serotonin and norepinephrine reuptake.

What remains uncertain: Knowing the transport effect does not tell us how much an individual will improve.

Serotonin · SERT

A membrane transporter with uptake reduced; messenger remains outside below the membrane. The separate terracotta symbol denotes a medicine, not its molecular shape. Serotonin: The messenger is shown outside the sending cell. SERT: The SERT transporter returns serotonin into the cell. Venlafaxine: uptake inhibited: The interrupted arrow names the action; the symbol is not a molecular shape or binding position.
  1. Serotonin

    The messenger is shown outside the sending cell.

  2. SERT

    The SERT transporter returns serotonin into the cell.

  3. Venlafaxine: uptake inhibited

    The interrupted arrow names the action; the symbol is not a molecular shape or binding position.

Simplified teaching model. Protein shapes, sizes, particle counts and arrows are illustrative, not measurements or experimental structures.

Norepinephrine · NET

A membrane transporter with uptake reduced; messenger remains outside below the membrane. The separate terracotta symbol denotes a medicine, not its molecular shape. Norepinephrine: The messenger is shown outside the sending cell. NET: The NET transporter returns norepinephrine into the cell. Venlafaxine: uptake inhibited: The interrupted arrow names the action; the symbol is not a molecular shape or binding position.
  1. Norepinephrine

    The messenger is shown outside the sending cell.

  2. NET

    The NET transporter returns norepinephrine into the cell.

  3. Venlafaxine: uptake inhibited

    The interrupted arrow names the action; the symbol is not a molecular shape or binding position.

Simplified teaching model. Protein shapes, sizes, particle counts and arrows are illustrative, not measurements or experimental structures.

Venlafaxine reduces serotonin and norepinephrine reuptake. Simplified illustration of the process; individual responses vary.
About this illustration

Venlafaxine inhibits serotonin and norepinephrine reuptake. Knowing the transport effect does not tell us how much an individual will improve.

A Closer Look at the Molecular Level

The body converts venlafaxine into O-desmethylvenlafaxine, often shortened to ODV and also known as desvenlafaxine. This is an active metabolite: a substance made as the body processes a medicine that still has effects of its own. Laboratory studies find that both venlafaxine and ODV inhibit serotonin and noradrenaline uptake and have weaker effects on the uptake of dopamine, another chemical messenger. The metabolite therefore forms part of venlafaxine’s overall action, rather than being an inactive waste product.

What is known: Both venlafaxine and its active metabolite contribute to the measured uptake effects.

What remains uncertain: The measured transport effects cannot predict how much an individual’s symptoms will improve.

From molecular action to clinical experience

  1. Molecular action
  2. Connected systems
  3. Individual outcome
Both venlafaxine and its active metabolite contribute to the measured uptake effects. Simplified illustration of the process; individual responses vary.
About this illustration

A known molecular action influences a complex system. The measured transport effects cannot predict how much an individual’s symptoms will improve.

A molecular effect cannot predict who will benefit.

No simple deficiency, dose-response curve or guarantee is shown.

How does it affect my body?

Noradrenergic effects can raise blood pressure and pulse. Digestion, sleep and sexual function may also be affected.

How does my body process it?

Venlafaxine’s half-life is about five hours and its active metabolite’s about eleven hours. Prolonged-release capsules slow absorption; they do not remove withdrawal risk.

How do treatment options differ?

Immediate-release and prolonged-release venlafaxine have different schedules. Switching between them needs a prescribing plan; the capsule strength alone does not define equivalent treatment.

A closer look at the science

Both venlafaxine and its metabolite O-desmethylvenlafaxine are active. Slower release changes absorption, not the identity of the active ingredient.

Venlafaxine hydrochloride is a salt of venlafaxine. The neutral parent has mirror-image forms; the drawing does not select a single stereoisomer and omits hydrochloride. A molecular drawing does not describe a product release system.

Chemical formula: C17H27NO2 · HCl

This formula describes the venlafaxine hydrochloride salt. Element symbols identify atoms; the dot separates the parent compound from the acid component. The drawing below shows the neutral parent, a different explicitly identified species. Chemical identity alone does not predict clinical benefit.

Verified 2D skeletal depiction of venlafaxine neutral parent; salt counterion is omitted.
NCBI PubChem CID 5656. Lines show bonds; unlabeled line ends and corners generally represent carbon and many hydrogens are omitted. This is chemical connectivity, not a binding pose.

The parent drawing omits the salt counterion. Formulation ingredients and release coatings are not depicted.

How was this medicine developed?

The cited Efexor XL authorisation dates from August 1997. Its release system supports once-daily administration while retaining venlafaxine’s interaction and withdrawal concerns.

Sources and References

  1. Efexor XL 75 mg: UK SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  2. Efexor XL 150 mg: UK SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  3. Efexor XL: patient leaflet

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  4. NHS: Venlafaxine

    Scope: NHS website for England — general medicine education, not a four-nation service pathway.

  5. NICE NG222: Depression in adults, recommendations

    Scope: England guidance; applicability or adoption in other UK nations requires separate consideration.

  6. Antidepressants: use and safety

    Scope: United Kingdom.

  7. Venlafaxine 75 mg immediate-release tablets — Dexcel UK SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  8. Venlafaxine 37.5 mg and 75 mg tablets — Dexcel UK patient leaflet

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  9. Venlafaxine XL 37.5 mg prolonged-release capsules — Genus UK SmPC

    Product information published on the electronic Medicines Compendium (emc); supplied by pharmaceutical companies.

    Scope: United Kingdom product information.

  10. FDA: Effexor XR prescribing information and Medication Guide
  11. NIH: What Is a Neurotransmitter?
  12. Depression in children and young people — recommendations

    Scope: United Kingdom; NICE recommendations require attention to national implementation and local pathways.

  13. MHRA Safety Roundup: ioflupane — venlafaxine and other SNRIs may affect DAT scan interpretation

    Scope: United Kingdom.

  14. DailyMed: Effexor XR extended-release capsules
  15. PubChem: Venlafaxine parent compound and verified 2D record
  16. A qualitative investigation into the effects of akathisia - Health Research Authority
  17. Extrapyramidal side effects- Management
  18. Anxiety and panic attacks - NHS
  19. Agitation: MedlinePlus Medical Encyclopedia

Shared scientific background. Some references are US product pharmacology or international chemical records; UK product details and prescribing information are verified separately.

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top